ArticleAnais brasileiros de dermatologia
Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2023Trial
- Skin health in oncology: evidence-based skin care for cancer patients.The oncologist · 2026Review
- Perspectives on managing skin manifestations in cancer patients: a multidisciplinary mixed-method survey of oncologists and dermatologists.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Cutaneous Reactions Following Anticancer Drug Therapy in a Tertiary Care Centre.JNMA; journal of the Nepal Medical Association · 2024Article
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Immune Reactions in Major Types of Oncological Treatment.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen.
objectiveTo evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment.
methodsA retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital.
resultsA total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. STUDY LIMITATIONS: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events.
conclusionA wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.